Podcasts about Figo

Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer. TRANSCRIPT Dr. Linda Duska: Hello, and welcome to the ASCO Daily News Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine.  On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really stirred some controversy over time, going all the way back more than 20 years: Should we be doing radical upfront surgery in advanced ovarian cancer, or should we be doing neoadjuvant chemotherapy? So, there was a lot of hype about the TRUST study, also called ENGOT ov33/AGO-OVAR OP7, a Phase 3 randomized study that compares upfront surgery with neoadjuvant chemotherapy followed by interval surgery. So, I want to talk about that study today. And joining me for the discussion is Dr. Kathleen Moore, a professor also of obstetrics and gynecology at the University of Oklahoma and the deputy director of the Stephenson Cancer Center, also at the University of Oklahoma Health Sciences.  Dr. Moore, it is so great to be speaking with you today. Thanks for doing this. Dr. Kathleen Moore: Yeah, it's fun to be here. This is going to be fun. Dr. Linda Duska: FYI for our listeners, both of our full disclosures are available in the transcript of this episode.  So let's just jump right in. We already alluded to the fact that the TRUST study addresses a question we have been grappling with in our field. Here's the thing, we have four prior randomized trials on this exact same topic. So, share with me why we needed another one and what maybe was different about this one? Dr. Kathleen Moore: That is, I think, the key question. So we have to level-set kind of our history. Let's start with, why is this even a question? Like, why are we even talking about this today? When we are taking care of a patient with newly diagnosed ovarian cancer, the aim of surgery in advanced ovarian cancer ideally is to prolong a patient's likelihood of disease-free survival, or if you want to use the term "remission," you can use the term "remission." And I think we can all agree that our objective is to improve overall survival in a way that also does not compromise her quality of life through surgical complications, which can have a big effect. The standard for many decades, certainly my entire career, which is now over 20 years, has been to pursue what we call primary cytoreductive surgery, meaning you get a diagnosis and we go right to the operating room with a goal of achieving what we call "no gross residual." That is very different – in the olden days, you would say "optimal" and get down to some predefined small amount of tumor. Now, the goal is you remove everything you can see.  The alternative strategy to that is neoadjuvant chemotherapy followed by interval cytoreductive surgery, and that has been the, quote-unquote, "safer" route because you chemically cytoreduce the cancer, and so, the resulting surgery, I will tell you, is not necessarily easy at all. It can still be very radical surgeries, but they tend to be less radical, less need for bowel resections, splenectomy, radical procedures, and in a short-term look, would be considered safer from a postoperative consideration. Dr. Linda Duska: Well, and also maybe more likely to be successful, right? Because there's less disease, maybe, theoretically. Dr. Kathleen Moore: More likely to be successful in getting to no gross residual. Dr. Linda Duska: Right. Yeah, exactly. Dr. Kathleen Moore: I agree with that. And so, so if the end game, regardless of timing, is you get to no gross residual and you help a patient and there's no difference in overall survival, then it's a no-brainer. We would not be having this conversation. But there remains a question around, while it may be more likely to get to no gross residual, it may be, and I think we can all agree, a less radical, safer surgery, do you lose survival in the long term by this approach? This has become an increasing concern because of the increase in rates of use of neoadjuvant, not only in this country, but abroad. And so, you mentioned the four prior studies. We will not be able to go through them completely. Dr. Linda Duska: Let's talk about the two modern ones, the two from 2020 because neither one of them showed a difference in overall survival, which I think we can agree is, at the end of the day, yes, PFS would be great, but OS is what we're looking for. Dr. Kathleen Moore: OS is definitely what we're looking for. I do think a marked improvement in PFS, like a real prolongation in disease-free survival, for me would be also enough. A modest improvement does not really cut it, but if you are really, really prolonging PFS, you should see that-  Dr. Linda Duska: -manifest in OS. Dr. Kathleen Moore: Yeah, yeah. Okay. So let's talk about the two modern ones. The older ones are EORTC and CHORUS, which I think we've talked about. The two more modern ones are SCORPION and JCOG0602. So, SCORPION was interesting. SCORPION was a very small study, though. So one could say it's underpowered. 170 patients. And they looked at only patients that were incredibly high risk. So, they had to have a Fagotti score, I believe, of over 9, but they were not looking at just low volume disease. Like, those patients were not enrolled in SCORPION. It was patients where you really were questioning, "Should I go to the OR or should I do neoadjuvant? Like, what's the better thing?" It is easy when it's low volume. You're like, "We're going." These were the patients who were like, "Hm, you know, what should I do?" High volume. Patients were young, about 55. The criticism of the older studies, there are many criticisms, but one of them is that, the criticism that is lobbied is that they did not really try. Whatever surgery you got, they did not really try with median operative times of 180 minutes for primary cytoreduction, 120 for neoadjuvant. Like, you and I both know, if you're in a big primary debulking, you're there all day. It's 6 hours. Dr. Linda Duska: Right, and there was no quality control for those studies, either. Dr. Kathleen Moore: No quality control. So, SCORPION, they went 451-minute median for surgery. Like, they really went for it versus four hours and then 253 for the interval, 4 hours. They really went for it on both arms. Complete gross resection was achieved in 50% of the primary cytoreduced. So even though they went for it with these very long surgeries, they only got to the goal half the time. It was almost 80% in the interval group. So they were more successful there. And there was absolutely no difference in PFS or OS. They were right about 15 months PFS, right about 40 months OS.  JCOG0602, of course, done in Japan, a big study, 300 patients, a little bit older population. Surprisingly more stage IV disease in this study than were in SCORPION. SCORPION did not have a lot of stage IV, despite being very bulky tumors. So a third of patients were stage IV. They also had relatively shorter operative times, I would say, 240 minutes for primary, 302 for interval. So still kind of short. Complete gross resection was not achieved very often. 30% of primary cytoreduction. That is not acceptable. Dr. Linda Duska: Well, so let's talk about TRUST. What was different about TRUST? Why was this an important study for us to see? Dr. Kathleen Moore: So the criticism of all of these, and I am not trying to throw shade at anyone, but the criticism of all of these is if you are putting surgery to the test, you are putting the surgeon to the test. And you are assuming that all surgeons are trained equally and are willing to do what it takes to get someone to no gross residual. Dr. Linda Duska: And are in a center that can support the post-op care for those patients. Dr. Kathleen Moore: Which can be ICU care, prolonged time. Absolutely. So when you just open these broadly, you're assuming everyone has the surgical skills and is comfortable doing that and has backup. Everybody has an ICU. Everyone has a blood bank, and you are willing to do that. And that assumption could be wrong. And so what TRUST said is, "Okay, we are only going to open this at centers that have shown they can achieve a certain level of primary cytoreduction to no gross residual disease." And so there was quality criteria. It was based on – it was mostly a European study – so ESGO criteria were used to only allow certified centers to participate. They had to have a surgical volume of over 36 cytoreductive surgeries per year. So you could not be a low volume surgeon. Your complete resection rates that were reported had to be greater than 50% in the upfront setting. I told you on the JCOG, it was 30%. Dr. Linda Duska: Right. So these were the best of the best. This was the best possible surgical situation you could put these patients in, right? Dr. Kathleen Moore: Absolutely. And you support all the things so you could mitigate postoperative complications as well. Dr. Linda Duska: So we are asking the question now again in the ideal situation, right? Dr. Kathleen Moore: Right. Dr. Linda Duska: Which, we can talk about, may or may not be generalizable to real life, but that's a separate issue because we certainly don't have those conditions everywhere where people get cared for with ovarian cancer. But how would you interpret the results of this study? Did it show us anything different? Dr. Kathleen Moore: I am going to say how we should interpret it and then what I am thinking about. It is a negative study. It was designed to show improvement in overall survival in these ideal settings in patients with FIGO stage IIIB and C, they excluded A, these low volume tumors that should absolutely be getting surgery. So FIGO stage IIIB and C and IVA and B that were fit enough to undergo radical surgery randomized to primary cytoreduction or neoadjuvant with interval, and were all given the correct chemo. Dr. Linda Duska: And they were allowed bevacizumab and PARP, also. They could have bevacizumab and PARP. Dr. Kathleen Moore: They were allowed bevacizumab and PARP. Not many of them got PARP, but it was distributed equally, so that would not be a confounder. And so that was important. Overall survival is the endpoint. It was a big study. You know, it was almost 600 patients. So appropriately powered. So let's look at what they reported. When they looked at the patients who were enrolled, this is a large study, almost 600 patients, 345 in the primary cytoreductive arm and 343 in the neoadjuvant arm. Complete resection in these patients was 70% in the primary cytoreductive arm and 85% in the neoadjuvant arm. So in both arms, it was very high. So your selection of site and surgeon worked. You got people to their optimal outcome. So that is very different than any other study that has been reported to date. But what we saw when we looked at overall survival was no statistical difference. The median was, and I know we do not like to talk about medians, but the median in the primary cytoreductive arm was 54 months versus 48 months in the neoadjuvant arm with a hazard ratio of 0.89 and, of course, the confidence interval crossed one. So this is not statistically significant. And that was the primary endpoint. Dr. Linda Duska: I know you are getting to this. They did look at PFS, and that was statistically significant, but to your point about what are we looking for for a reasonable PFS difference? It was about two months difference. When I think about this study, and I know you are coming to this, what I thought was most interesting about this trial, besides the fact that the OS, the primary endpoint was negative, was the subgroup analyses that they did. And, of course, these are hypothesis-generating only. But if you look at, for example, specifically only the stage III group, that group did seem to potentially, again, hypothesis generating, but they did seem to benefit from upfront surgery.  And then one other thing that I want to touch on before we run out of time is, do we think it matters if the patient is BRCA germline positive? Do we think it matters if there is something in particular about that patient from a biomarker standpoint that is different? I am hopeful that more data will be coming out of this study that will help inform this. Of course, unpowered, hypothesis-generating only, but it's just really interesting. What do you think of their subset analysis? Dr. Kathleen Moore: Yeah, I think the subsets are what we are going to be talking about, but we have to emphasize that this was a negative trial as designed. Dr. Linda Duska: Absolutely. Yes. Dr. Kathleen Moore: So we cannot be apologists and be like, "But this or that." It was a negative trial as designed. Now, I am a human and a clinician, and I want what is best for my patients. So I am going to, like, go down the path of subset analyses. So if you look at the stage III tumors that got complete cytoreduction, which was 70% of the cases, your PFS was almost 28 months versus 21.8 months. Dr. Linda Duska: Yes, it becomes more significant. Dr. Kathleen Moore: Yeah, that hazard ratio is 0.69. Again, it is a subset. So even though the P value here is statistically significant, it actually should not have a P value because it is an exploratory analysis. So we have to be very careful. But the hazard ratio is 0.69. So the hypothesis is in this setting, if you're stage III and you go for it and you get someone to no gross residual versus an interval cytoreduction, you could potentially have a 31% reduction in the rate of progression for that patient who got primary cytoreduction. And you see a similar trend in the stage III patients, if you look at overall survival, although the post-progression survival is so long, it's a little bit narrow of a margin.  But I do think there are some nuggets here that, one of our colleagues who is really one of the experts in surgical studies, Dr. Mario Leitao, posted this on X, and I think it really resonated after this because we were all saying, "But what about the subsets?" He is like, "It's a negative study." But at the end of the day, you are going to sit with your patient. The patient should be seen by a GYN oncologist or surgical oncologist with specialty in cytoreduction and a medical oncologist, you know, if that person does not give chemo, and the decision should be made about what to do for that individual patient in that setting. Dr. Linda Duska: Agreed. And along those lines, if you look carefully at their data, the patients who had an upfront cytoreduction had almost twice the risk of having a stoma than the patients who had an interval cytoreduction. And they also had a higher risk of needing to have a bowel resection. The numbers were small, but still, when you look at the surgical complications, as you've already said, they're higher in the upfront group than they are in the interval group. That needs to be taken into account as well when counseling a patient, right? When you have a patient in front of you who says to you, "Dr. Moore, you can take out whatever you want, but whatever you do, don't make me a bag." As long as the patient understands what that means and what they're asking us to do, I think that we need to think about that. Dr. Kathleen Moore: I think that is a great point. And I have definitely seen in our practice, patients who say, "I absolutely would not want an ostomy. It's a nonstarter for me." And we do make different decisions. And you have to just say, "That's the decision we've made," and you kind of move on, and you can't look back and say, "Well, I wish I would have, could have, should have done something else." That is what the patient wants. Ultimately, that patient, her family, autonomous beings, they need to be fully counseled, and you need to counsel that patient as to the site that you are in, her volume of disease, and what you think you can achieve. In my opinion, a patient with stage III cancer who you have the site and the capabilities to get to no gross residual should go to the OR first. That is what I believe. I do not anymore think that for stage IV. I think that this is pretty convincing to me that that is probably a harmful thing. However, I want you to react to this. I think I am going to be a little unpopular in saying this, but for me, one of the biggest take-homes from TRUST was that whether or not, and we can talk about the subsets and the stage III looked better, and I think it did, but both groups did really well. Like, really well. And these were patients with large volume disease. This was not cherry-picked small volume stage IIIs that you could have done an optimal just by doing a hysterectomy. You know, these were patients that needed radical surgery. And both did well. And so what it speaks to me is that anytime you are going to operate on someone with ovary, whether it be frontline, whether it be a primary or interval, you need a high-volume surgeon. That is what I think this means to me. Like, I would want high volume surgeon at a center that could do these surgeries, getting that patient, my family member, me, to no gross residual. That is important. And you and I are both in training centers. I think we ought to take a really strong look at, are we preparing people to do the surgeries that are necessary to get someone to no gross residual 70% and 85% of the time? Dr. Linda Duska: We are going to run out of time, but I want to address that and ask you a provocative question. So, I completely agree with what you said, that surgery is important. But I also think one of the reasons these patients in this study did so well is because all of the incredible new therapies that we have for patients. Because OS is not just about surgery. It is about surgery, but it is also about all of the amazing new therapies we have that you and others have helped us to get through clinical research. And so, how much of that do you think, like, for example, if you look at the PFS and OS rates from CHORUS and EORTC, I get it that they're, that they're not the same. It's different patients, different populations, can't do cross-trial comparisons. But the OS, as you said, in this study was 54 months and 48 months, which is, compared to 2010, we're doing much, much better. It is not just the surgery, it is also all the amazing treatment options we have for these patients, including PARP, including MIRV, including lots of other new therapies. How do you fit that into thinking about all of this? Dr. Kathleen Moore: I do think we are seeing, and we know this just from epidemiologic data that the prevalence of ovarian cancer in many of the countries where the study was done is increasing, despite a decrease in incidence. And why is that? Because people are living longer. Dr. Linda Duska: People are living longer, yeah. Dr. Kathleen Moore: Which is phenomenal. That is what we want. And we do have, I think, better supportive care now. PARP inhibitors in the frontline, which not many of these patients had. Now some of them, this is mainly in Europe, will have gotten them in the first maintenance setting, and I do think that impacts outcome. We do not have that data yet, you know, to kind of see what, I would be really interested to see. We do not do this well because in ovarian cancer, post-progression survival can be so long, we do not do well of tracking what people get when they come off a clinical trial to see how that could impact – you know, how many of them got another surgery? How many of them got a PARP? I think this group probably missed the ADC wave for the most part, because this, mirvetuximab is just very recently available in Europe. Dr. Linda Duska: Unless they were on trial. Dr. Kathleen Moore: Unless they were on trial. But I mean, I think we will have to see. 600 patients, I would bet a lot of them missed the ADC wave. So, I do not know that we can say we know what drove these phenomenal – these are some of the best curves we've seen outside of BRCA. And then coming back to your point about the BRCA population here, that is a really critical question that I do not know that we're ever going to answer. There have been hypotheses around a tumor that is driven by BRCA, if you surgically cytoreduced it, and then chemically cytoreduced it with chemo, and so you're starting PARP with nothing visible and likely still homogeneous clones. Is that the group we cured? And then if you give chemo first before surgery, it allows more rapid development of heterogeneity and more clonal evolution that those are patients who are less likely to be cured, even if they do get cytoreduced to nothing at interval with use of PARP inhibitor in the front line. That is a question that many have brought up as something we would like to understand better. Like, if you are BRCA, should you always just go for it or not? I do not know that we're ever going to really get to that. We are trying to look at some of the other studies and just see if you got neoadjuvant and you had BRCA, was anyone cured? I think that is a question on SOLO1 I would like to know the answer to, and I don't yet, that may help us get to that. But that's sort of something we do think about. You should have a fair number of them in TRUST. It wasn't a stratification factor, as I remember. Dr. Linda Duska: No, it wasn't. They stratified by center, age, and ECOG status Dr. Kathleen Moore: So you would hope with randomization that you would have an equal number in each arm. And they may be able to pull that out and do a very exploratory look. But I would be interested to see just completely hypothesis-generating what this looks like for the patients with BRCA, and I hope that they will present that. I know they're busy at work. They have translational work. They have a lot pending with TRUST. It's an incredibly rich resource that I think is going to teach us a lot, and I am excited to see what they do next. Dr. Linda Duska: So, outside of TRUST, we are out of time. I just want to give you a moment if there were any other messages that you want to share with our listeners before we wrap up. Dr. Kathleen Moore: It's an exciting time to be in GYN oncology. For so long, it was just chemo, and then the PARP inhibitors nudged us along quite a bit. We did move more patients, I believe, to the cure fraction. When we ultimately see OS, I think we'll be able to say that definitively, and that is exciting. But, you know, that is the minority of our patients. And while HRD positive benefits tremendously from PARP, I am not as sure we've moved as many to the cure fraction. Time will tell. But 50% of our patients have these tumors that are less HRD. They have a worse prognosis. I think we can say that and recur more quickly. And so the advent of these antibody-drug conjugates, and we could name 20 of them in development in GYN right now, targeting tumor-associated antigens because we're not really driven by mutations other than BRCA. We do not have a lot of things to come after. We're not lung cancer. We are not breast cancer. But we do have a lot of proteins on the surface of our cancers, and we are finally able to leverage that with some very active regimens. And we're in the early phases, I would say, of really understanding how best to use those, how best to position them, and which one to select for whom in a setting where there is going to be obvious overlap of the targets. So we're going to be really working this problem. It is a good problem. A lot of drugs that work pretty well. How do you individualize for a patient, the patient in front of you with three different markers? How do you optimize it? Where do you put them to really prolong survival? And then we finally have cell surface. We saw at ASCO, CDK2 come into play here for the first time, we've got a cell cycle inhibitor. We've been working on WEE1 and ATR for a long time. CDK2s may hit. Response rates were respectable in a resistant population that was cyclin E overexpressing. We've been working on that biomarker for a long time with a toxicity profile that was surprisingly clean, which I like to see for our patients. So that is a different platform. I think we have got bispecifics on the rise. So there is a pipeline of things behind the ADCs, which is important because we need more than one thing, that makes me feel like in the future, I am probably not going to be using doxil ever for platinum-resistant disease. So, I am going to be excited to retire some of those things. We will say, "Remember when we used to use doxil for platinum-resistant disease?" Dr. Linda Duska: I will be retired by then, but thanks for that thought. Dr. Kathleen Moore: I will remind you. Dr. Linda Duska: You are right. It is such an incredibly exciting time to be taking care of ovarian cancer patients with all the opportunities.  And I want to thank you for sharing your valuable insights with us on this podcast today and for your great work to advance care for patients with GYN cancers. Dr. Kathleen Moore: Likewise. Thanks for having me. Dr. Linda Duska: And thank you to our listeners for your time today. You will find links to the TRUST study and other studies discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:   Dr. Linda Duska  @Lduska Dr. Kathleen Moore Follow ASCO on social media:     @ASCO on X (formerly Twitter) ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures of Potential Conflicts of Interest:    Dr. Linda Duska:   Consulting or Advisory Role: Regeneron, Inovio Pharmaceuticals, Merck, Ellipses Pharma  Research Funding (Inst.): GlaxoSmithKline, Millenium, Bristol-Myers Squibb, Aeterna Zentaris, Novartis, Abbvie, Tesaro, Cerulean Pharma, Aduro Biotech, Advaxis, Ludwig Institute for Cancer Research, Leap Therapeutics  Patents, Royalties, Other Intellectual Property: UptToDate, Editor, British Journal of Ob/Gyn  Dr. Kathleen Moore: Leadership: GOG Partners, NRG Ovarian Committee Chair Honoraria: Astellas Medivation, Clearity Foundation, IDEOlogy Health, Medscape, Great Debates and Updates, OncLive/MJH Life Sciences, MD Outlook, Curio Science, Plexus, University of Florida, University of Arkansas for Medical Sciences, Congress Chanel, BIOPHARM, CEA/CCO, Physician Education Resource (PER), Research to Practice, Med Learning Group, Peerview, Peerview, PeerVoice, CME Outfitters, Virtual Incision Consulting/Advisory Role: Genentech/Roche, Immunogen, AstraZeneca, Merck, Eisai, Verastem/Pharmacyclics, AADi, Caris Life Sciences, Iovance Biotherapeutics, Janssen Oncology, Regeneron, zentalis, Daiichi Sankyo Europe GmbH, BioNTech SE, Immunocore, Seagen, Takeda Science Foundation, Zymeworks, Profound Bio, ADC Therapeutics, Third Arc, Loxo/Lilly, Bristol Myers Squibb Foundation, Tango Therapeutics, Abbvie, T Knife, F Hoffman La Roche, Tubulis GmbH, Clovis Oncology, Kivu, Genmab/Seagen, Kivu, Genmab/Seagen, Whitehawk, OnCusp Therapeutics, Natera, BeiGene, Karyopharm Therapeutics, Day One Biopharmaceuticals, Debiopharm Group, Foundation Medicine, Novocure Research Funding (Inst.): Mersana, GSK/Tesaro, Duality Biologics, Mersana, GSK/Tesaro, Duality Biologics, Merck, Regeneron, Verasatem, AstraZeneca, Immunogen, Daiichi Sankyo/Lilly, Immunocore, Torl Biotherapeutics, Allarity Therapeutics, IDEAYA Biosciences, Zymeworks, Schrodinger Other Relationship (Inst.): GOG Partners

Im zweiten Teil unseres Specials setzen wir unsere Reise durch die Karriere von Zinedine Zidane fort. Nach seinem Triumph bei der EM 2000 stand der nächste große Schritt an: der Wechsel zu Real Madrid für damals unfassbare 77,5 Millionen Euro. Wir sprechen über seine Zeit bei den Galaktischen, seinen legendären Volleytreffer im Champions-League-Finale 2002 gegen Leverkusen und seine Rolle im Starensemble mit Figo, Raul und Ronaldo. Natürlich darf auch die WM 2006 nicht fehlen, bei der Zidane Frankreich ins Finale führte, dort als bester Spieler des Turniers ausgezeichnet wurde und seine Karriere mit jenem berühmten Kopfstoß gegen Materazzi beendete. Abschließend werfen wir einen Blick auf Zidanes beeindruckende Trainerkarriere bei Real Madrid. Von seinem Einstieg als Berater und Co-Trainer unter Ancelotti bis hin zu seinem historischen Champions-League-Hattrick als Cheftrainer zwischen 2016 und 2018. Wir diskutieren seinen Stellenwert als Trainer, seinen Beitrag zu Reals Erfolgen und was die Zukunft für Zizou bringen könnte. Außerdem haben wir die Großen 10 Ausraster im Fußball dabei und natürlich auch ein Getränk der Episode verkostet. Viel Spaß beim Hören!

En este episodio, Figo reflexiona sobre el documental de NETFLIX sobre el chamán californiano, casado con la princesa de Noruega, y cómo este muestra las diferencias culturales en la forma en que se establece la cordialidad y la amistad en este país. A través de su narrativa, Figo explora la distancia emocional que caracteriza a la cultura noruega, la importancia de la integración y el papel que juegan los inmigrantes en la sociedad. También discute la naturaleza de las relaciones laborales y cómo estas difieren de las expectativas latinoamericanas, enfatizando la necesidad de mostrar interés y paciencia para ser aceptado en un nuevo entorno.Capítulos:00:00 Introducción al Chamán Real Noruego02:48 Cultura Noruega y la Distancia Emocional06:00 Expectativas de Bienvenida en Noruega08:52 El Rol del Inmigrante en la Sociedad Noruega11:44 Reflexiones Finales sobre la Integración

El Terror Migrante

En este episodio del podcast, Marcela y Figo exploran el impacto cultural de '31 Minutos', un programa chileno de marionetas que combina humor y crítica social. Discuten cómo el arte puede servir como una forma de resistencia y subversión, especialmente en el contexto de la migración y la identidad latina. A través de anécdotas y reflexiones, destacan la importancia de apoyar la cultura latina y la creatividad en la expresión artística.Capítulos00:00 Bienvenida y Presentación del Podcast00:59 El Fenómeno de 31 Minutos en el TinyDesk03:19 Humor y Crítica Social en 31 Minutos06:12 Impacto del Tiny Desk Concert09:31 La Relevancia Cultural de 31 Minutos12:15 La Hispanidad en Estados Unidos12:48 Conexiones Culturales en Latinoamérica13:43 La Influencia de la Cultura Estadounidense16:23 Apoyo entre Latinos: Un Llamado a la Unidad17:20 El Valor de la Cultura Latinoamericana18:11 Desafíos de la Inmigración y la Identidad21:35 El Humor como Herramienta de Reflexión23:55 La Misión del Arte en la SociedadEl show de #31minutos en el #tinydesk lo puedes ver aquí:https://www.youtube.com/watch?v=UEqTIwRrWvA&list=RDUEqTIwRrWvA&start_radio=1

Oggi faremo un viaggio con Bello Figo, artista che ha portato la trap in Italia quando ancora nessuno sapeva cosa fosse. Dietro il personaggio che tutti conoscono c'è un ragazzo che ha trovato nella musica l'unico modo per esprimersi davvero.Una storia fatta di scelte controcorrente, di momenti in cui ha dovuto fare i conti con narrazioni che non gli appartenevano e con la paura di perdere ciò che ha costruito. Una conversazione che parla di identità, di paura di perdere ciò che si è costruito e di come a volte sia proprio un personaggio a salvarti. Puoi iniziare un percorso su Serenis per prenderti cura del tuo benessere mentale a un prezzo convenzionato. Scopri di più su: https://www.serenis.it/influencer/one-more-time?utm_source=influencer&utm_medium=affiliate&utm_campaign=ONEMORETIME7&utm_content=podcast&utm_term=host+read Il dream team di One More Time è composto da: Samar Abdel Basset, Davide Tessari, Alice Gagliardi, Tommaso Galli, Noemi Grandi, Edoardo Levy, Gloria Giovanditti, Leila Stabile, Giovanni Zaccaria.Questo episodio contiene l’inserimento di prodotti e servizi a fini commerciali.See omnystudio.com/listener for privacy information.

Nagyon ráálltak az ügyészségek, hogy több százezres költséget varrjanak az elterelést végigcsináló drogfogyasztók nyakába Egymilliárd eurós főnyeremény után jött a krach Kifosztották Majkát a Tizenkét okos emberben – Nem is akárhogyan! Arany, Trump, AI és háborúk: 5 nélkülözhetetlen tanács a befektetőknek Megvan az eddigi legjobb akkumulátor az elektromos autókba: a Volkswagen dicsekszik vele, de Kínáé az érdem – egymillió kilométert is kibír Kedvesen üzen a magyar autósoknak egy rendőr Farkasfalkák a világtengereken - de vajon az orosz vagy az amerikai az erősebb? Luís Figo rejtélyes üzenetet hagyott: Azt hiszem, eljött az idő Szoboszlai minden titkot elárult a mezcseréről, egy dolog miatt viszont aggódott A hét közepe még nem a változásról szól A további adásainkat keresd a podcast.hirstart.hu oldalunkon. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nagyon ráálltak az ügyészségek, hogy több százezres költséget varrjanak az elterelést végigcsináló drogfogyasztók nyakába Egymilliárd eurós főnyeremény után jött a krach Kifosztották Majkát a Tizenkét okos emberben – Nem is akárhogyan! Arany, Trump, AI és háborúk: 5 nélkülözhetetlen tanács a befektetőknek Megvan az eddigi legjobb akkumulátor az elektromos autókba: a Volkswagen dicsekszik vele, de Kínáé az érdem – egymillió kilométert is kibír Kedvesen üzen a magyar autósoknak egy rendőr Farkasfalkák a világtengereken - de vajon az orosz vagy az amerikai az erősebb? Luís Figo rejtélyes üzenetet hagyott: Azt hiszem, eljött az idő Szoboszlai minden titkot elárult a mezcseréről, egy dolog miatt viszont aggódott A hét közepe még nem a változásról szól A további adásainkat keresd a podcast.hirstart.hu oldalunkon. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Lançado em Outubro de 2025 pelo FIGO, OMS e ICM lançaram um novo protocolo de hemorragia puerperal que tenta unificar as condutas, trazer novidades e organizar melhor o cuidado no pós parto e o dr. Carlos Martins vem atualizar esse tema conosco. Espero que Gostem.Episódio patrocinado pela equipe MedCof GO e com o cupom ESPECULANDO vocês conseguem R$300 de desconto nos cursos para R+ de GO, Mastologia e para o TEGO: https://tego.grupomedcof.com.br

Ça coûte combien, Dr ?La mini-série

Alle soglie della pausa nazionali ripercorriamo lo spettacolo di Chelsea-Liverpool e quanto ci sta divertendo il Bournemouth di Iraola. Parliamo finalmente delle stagioni di Fulham e Leeds e commentiamo anche Crystal Palace-Everton. Britannia è il podcast dedicato alla Premier League, pensato per chi vuole restare aggiornato su tutto quello che succede nel calcio d'Oltremanica con il giusto mix di analisi, curiosità e ironia.Ogni settimana, Alessandro Giura, Federico Sborchia e Nicola Lozupone raccontano storie, statistiche e retroscena del campionato più seguito al mondo.Dai top club alle neopromosse, dalle leggende alle giovani promesse: ti raccontiamo tutto quello che accade in Premier League prima degli altri per bullarti con gli amici.Seguici anche su:YouTube: @BritanniaPodcastTwitter/X: @BritanniaPodInstagram: @BritanniaPodcastMusic track: City Lights by AylexSource: https://freetouse.com/music

Miki Noëlle ha estat el nou convidat del Bacstage de Flaixbac! L'artista barceloní ha visitat el programa per parlar del seu recorregut com a creador d'art urbà i interactiu i per presentar-nos el seu llibre “BarçArt”. Amb més de nou anys d'experiència i col·laboracions amb marques com FC Barcelona, Disney, Vans o Seat, Miki Noëlle ens ha explicat com dona vida a les seves obres —des d'il·lustracions fins a murals en directe— i ens ha descobert les històries que s'amaguen darrere dels seus dibuixos!#BarçArt #MikiNoelle #LamineYamal #Barça00:00 a 01:00 Intro01:00 a 04:05 Parlem del llibre BarçArt i la presentació!!!04:05 a 06:07 Nous projectes i no poder comercialitzar els dibuixos del Barça06:07 a 07:50 Lamine Yamal es posa un sticker seu de perfil a Instagram07:50 a 08:50 Tenir el Figo molt a prop a Montjuïc08:50 a 10:24 Dibuixar tatuatges10:24 a 11:40 Conèixer el creador de la mascota del Barça: CAT11:40 a 13:40 El seu compte secundari: @rafitheraccoon13:40 a 14:30 Col·laborar amb altres equips de futbol14:30 a 16:30 Il·lustracions prèvies als partits del Barça16:30 a 19:17 El Test del Bacstage19:17 a 25:04 El Test del Mòbil

Mashirika ya afya duniani yametoa miongozo mipya yenye lengo la kuokoa maisha ya maelfu ya wanawake wanaopoteza maisha kutokana na kutokwa damu nyingi baada ya kujifungua hali inayojulikana kama postpartum haemorrhage au PPH. Tupate taarifa zaidi kutoka kwa Leah Mushi.

En este episodio, Figo reflexiona sobre la percepción de seguridad en Noruega tras un incidente violento en Oslo. A través de su experiencia personal, explora cómo la imagen de un país pacífico puede contrastar con la realidad de ciertos eventos violentos. También discute el impacto de los medios de comunicación en la percepción de la seguridad y cómo la narrativa nacional puede influir en la tranquilidad de sus habitantes. Finalmente, invita a los oyentes a considerar cómo la información que consumen puede afectar su bienestar emocional y su percepción de la realidad.Capítulos:00:00 Bienvenida y Reflexiones Iniciales01:24 Percepción de Noruega como un País Seguro07:13 La Realidad de la Seguridad en Noruega12:06 Narrativas y Medios en Noruega16:28 Cierre y Reflexiones Finales

En este episodio del podcast, Marcela y Figo discuten sobre la experiencia de migrar a Noruega, centrándose en la adaptación al calendario noruego, la importancia de la planificación y las diferencias en las vacaciones en comparación con Latinoamérica. A través de anécdotas personales, comparten consejos sobre cómo manejar la vida laboral y familiar en un nuevo país, así como la importancia de la comunicación efectiva en un idioma extranjero.CAPÍTULOS:00:00 Introducción al Podcast y Temática del Episodio00:56 Adaptación al Calendario Noruego04:25 Experiencias Personales con el Calendario09:39 Errores y Aprendizajes en la Planificación14:48 Técnicas de Comunicación y Confirmación18:12 Vacaciones en Noruega vs. Latinoamérica18:51 Vacaciones en Noruega: Estructura y Organización24:20 Actividades y Beneficios del SFU para Niños27:22 La Primavera y sus Vacaciones en Noruega29:54 Días Feriados y Celebraciones Noruegas34:05 Consejos para Viajar en Temporada Alta

En este episodio, Marcela y Figo exploran la vital importancia de construir capital social y cultural al emigrar. A través de sus experiencias personales, comparten cómo establecer conexiones significativas y comprender las tradiciones locales puede transformar la experiencia migratoria. Descubre estrategias para integrarte en una nueva comunidad y cómo estas relaciones pueden enriquecer tu vida en el extranjero. ¡No te lo pierdas! Encuentra el episodio en Spotify, Apple Podcast y YouTube.

O Pedro Fragoso e o Rui Silva travaram nova batalha, agora com olhos no Euro-2000. Tiveram de escolher onze jogadores, cinco suplentes e um selecionador e, dizem as más línguas, o trunfo poderá estar nos laterais. Zidane contra Figo, Toldo contra Schmeichel, Kluivert contra Larsson… quem terá levado a melhor? Deixem-nos as vossas opiniões nos comentários e sugiram novos episódios.

Portugal foi campeão mundial de sub-20 pela segunda vez consecutiva em 1991. Carlos Queiroz estava ao leme de toda a formação da federação e os resultados continuaram a aparecer. Com João Pinto, Figo e Rui Costa em plano de destaque, havia muitos outros talentos promissores que acabaram por deixar a marca na história do futebol português. O legado eternizou-se e continua a resistir mesmo quando algumas das suas figuras, como Jorge Costa, começam a desaparecer. Neste episódio, o Nuno Madureira e o Rui Silva abordam o que fez desta equipa campeã, as diferenças para a equipa de 1989 e as pegadas que deixaram para as gerações seguintes.

Aquest 24 de juliol ha fet 25 anys que el capità del Barça, Luis Figo, es va posar la samarreta del Reial Madrid. Aquell episodi va disparar la rivalitat entre els dos clubs, provocant imatges de violència contra el jugador blanc. Els mitjans de comunicació van alimentar aquesta polèmica, segons Joan Maria Pou i Ramon Besa.

EBD PECC IEADAM 3º TRIM 2025 | Lição 5: "Juízo, restauração e os dois cestos de figo."

It's an episode of big names and exclusive name drops as iGaming Daily, supported by Optimove, welcomes SBC's CEO and Founder, Rasmus Sojmark, to dig deeper into the Legends Charity Game in Lisbon this September.  Rasmus delves deeper into, what will be, an unforgettable night of football as SBC proudly presents the Legends Charity Game, a historic showdown between the World Legends and Portugal Legends, taking place on Monday, September 15th in Lisbon. The event aims to raise over €1 million for global communities affected by conflict and war, blending the magic of the beautiful game with a powerful humanitarian mission. The pitch will be graced by football royalty. The Portugal Legends, led by Luís Figo, will reunite stars from the iconic Euro 2004 squad, including Deco, Quaresma, Victor Baía, and more. On the other side, the World Legends, managed by Peter Schmeichel and Diego Lugano, will feature Ronaldinho, Cafu, Zanetti, Hagi, Van der Sar, and Henrik Larsson, just to name a few. One of the most anticipated storylines? Greece's Georgios Karagounis faces the very players he defeated in the Euro 2004 final. The Legends Charity Game also kicks off the SBC Summit Lisbon (Sept 16–18), the biggest B2B iGaming event of the year. The summit will host 700 exhibitors, eight conference stages, and 30,000+ attendees. Highlights include a Super Stage press event with the football legends, live music, free food, and headline performances from Joel Corry, Timmy Trumpet, Imanbek, Alok, and The Blackouts.Click here to purchase tickets for the Legends Charity Game To read more on the Legends Charity Game click on the following link:- https://sbcnews.co.uk/europe/2025/07/17/legends-charity-game-lisbon/Host: Joe StreeterGuest: Rasmus Sojmark Producer: Anaya McDonaldEditor: James Ross

Send us a textThis tribute story is for all those whom Diogo Jota touched.It is strange to feel connected to a person most of us have never met. Although, I suppose our connection to him is what binds us.As we were reading about Diogo's life, one thing was clear. Whether he was in Porto, Wolverhampton, Liverpool or with the Portugese National Team, Diogo was able to build close bonds with those around him. So many remembered his friendship more than anything else.Oh, he wears the number 20,He will take us to victory,And when he's running down the left wing,He'll cut inside and score for LFC.He's a lad from Portugal,Better than Figo don't you know,Oh, his name is Diogo!#YNWA #20 Support the showSupport the show! Become a member and have access to fan art, new episodes, shout outs, story input, educational resources and the Soccer Bedtime Community. To become a Soccer Bedtime Stories Member Visit us at Buzzsprout!We would love to hear from you and connect with other soccer/football lovers from around the world! Leave a comment, email or find us on social media.Find us on Instagram: MySoccerBedtimeFind us on Facebook: SoccerBedtimeStoriesAlso excited to launch our first story coloring pages, you can find them at: The Soccer Teacher by Soccer Bedtime Stories

The Liverbirds return to try and make sense of the truly dreadful loss of Diogo Jota and his brother Andre Silva. One of the most difficult pods we've done, but Gae, Randi and Amy Kate reminisce and pay their own tribute to our no. 20, the lad from Portugal, who was better than Figo, don't you know.Rest well Diogo. & Andre. Learn more about your ad choices. Visit podcastchoices.com/adchoices

En este episodio, Figo comparte cinco frases que han sido fundamentales en su experiencia como migrante en Noruega. A través de citas de filósofos y conceptos psicológicos, se exploran temas como la importancia de la reacción ante las circunstancias, la mentalidad de crecimiento, la gestión de expectativas y la adaptación al nuevo entorno. Cada frase ofrece una perspectiva valiosa para quienes enfrentan el desafío de la migración.Capítulos:00:00 Introducción a las Frases Inspiradoras02:40 La Reacción ante las Circunstancias05:58 Mentalidad de Crecimiento y el 'Aún No'08:50 El Terreno Sin Salida11:45 Expectativas y Realidad en la Migración14:59 Adaptación al Clima y la Reacción Personal

Os figos são doces e populares, mas será que fazem bem à saúde? E qual a melhor escolha: figos frescos ou secos? A nutricionista Mariana Chaves esclarece.See omnystudio.com/listener for privacy information.

Dr. John Sweetenham shares highlights from Day 4 of the 2025 ASCO Annual Meeting, including new research on maintenance therapy in small cell lung cancer and a virtual reality psychosocial intervention for patients undergoing hematopoietic stem cell transplantation. Transcript Hello, I'm Dr. John Sweetenham, the host of the ASCO Daily News Podcast, with my takeaways on selected abstracts from Day 4 of the 2025 ASCO Annual Meeting. My disclosures are available in the transcript of this episode. Today's selection features reports of 3 randomized trials in very different clinical settings: maintenance therapy in extensive small cell lung cancer (SCLC), upfront surgery in advanced ovarian cancer, and a supportive care intervention for patients undergoing hematopoietic stem cell transplantation. The first of these studies, Abstract 8006, was presented by Dr. Luis Paz-Ares from the University Hospital [October 12] in Madrid, Spain, and reports the primary results of the IMforte trial. This was a phase 3 trial evaluating the combination of lurbinectedin and atezolizumab as first-line maintenance therapy in patients with extensive small cell lung cancer. Despite some improvements in the first-line treatment of extensive small cell lung cancer with the use of checkpoint inhibitors in combination with platinum-based chemotherapy, most of the patients experience early disease progression and long-term survival remains very limited. This provides a rationale for considering a maintenance intervention. Lurbinectedin is an alkylating agent and transcription inhibitor [that is] already approved in the United States for patients with relapsed/refractory metastatic SCLC following platinum-based chemotherapy. It has been shown to synergize with immune checkpoint inhibitors in pre-clinical studies and has also been evaluated in early-phase clinical trials. The IMforte trial is a global, randomized trial in which patients are initially treated with atezolizumab, and those patients who do not progress on induction therapy are then randomized to maintenance therapy with atezolizumab alone or atezolizumab with lurbinectedin. The primary endpoints of the study were progression-free and overall survival. Four hundred and eighty-three patients were randomized and at a median follow-up of 15 months, the median progression-free survival for patients who received the combination was 5.4 months and the median overall survival was 13.2 months. This compares with 2.1 and 10.6 months, respectively, in patients who received atezolizumab only. The lurbinectedin and atezolizumab combination was generally well-tolerated, with no new or unexpected safety signals. The benefit was consistent in magnitude across all the relevant patient subgroups. This is the first phase 3 study to show a progression-free and overall survivial improvement with first-line maintenance in extensive stage SCLC and the result is likely to be practice-changing, establishing a new standard of care in this tough-to-treat disease. Next up is LBA5500, presented by Dr. Sven Mahner from LMU University in Munich, Germany. This describes the results of the TRUST study, a randomized trial of upfront surgical therapy in advanced ovarian cancer. As background, total macroscopic tumor resection with maximal effort cytoreductive surgery is the cornerstone of treatment in patients with advanced ovarian cancer. The optimal timing of such surgery remains controversial, whether it's more beneficial as a primary cytoreductive surgery before chemotherapy or in the form of interval cytoreductive surgery after 3 cycles of neoadjuvant chemotherapy. Previous studies have addressed this issue, but results have been confounded by issues of patient and center selection. The TRUST study is a randomized, international, multicenter phase 3 trial that compares the outcomes of the timing of surgery in surgically fit patients with seemingly resectable FIGO stage IIIB/IVB ovarian, tubal, and peritoneal carcinoma. To ensure consistent and adequate surgical quality, participating centers in the trial were required to obtain accreditation and undergo an onsite quality assurance review. This included assessment of infrastructure, surgical proficiency, complete resection rates, and surgical volume. Seven hundred and ninety-seven patients with advanced ovarian cancer were randomized to undergo surgery prior to therapy with 6 cycles of carboplatin and paclitaxel along with bevacizumab and a PARP inhibitor, or to have the surgery between the third and fourth cycle of the same systemic therapy. Of the initial 797 patients, 688 comprised the intent-to-treat population, of whom 345 received primary cytoreductive surgery and 343 received neoadjuvant chemotherapy followed by interval cytoreductive surgery.  The results show that patients undergoing primary surgery had significantly improved progression-free survival compared with those who had interval cytoreductive surgery (median progression-free survival was 22.1 months versus 19.7 months). No difference in overall survival was observed between the 2 arms of the study.  This is the first study to show a benefit for primary cytoreductive surgery, although the progression-free survival improvement was not reflected in an overall survival difference. A subgroup analysis for patients who underwent complete cytoreduction suggests a progression-free survival and survival benefit, although it isn't clear to me that the study was powered for this endpoint. Nevertheless, these are very difficult studies to perform, and the investigators should be congratulated for this robustly conducted clinical trial. Today's final abstract is 1504, presented by Dr. Hermioni Amonoo from Harvard Medical School. The trial evaluated BMT-VR, a virtual reality psychosocial intervention for patients undergoing bone marrow transplantation. This randomized trial included adult patients undergoing autologous and allogeneic transplantation. The BMT-VR platform included, among others, modules addressing psychoeducation, coping, acceptance, and gratitude. BMT-VR patients were provided with VR headsets and completed all modules during their hospitalization. Patient-reported outcomes were then assessed at 2, 4, 12, and 24 weeks post-BMT. Use of the VR tool was tracked during hospitalization. Control patients received usual care during their hospital stay and were then assessed at the same intervals post-BMT.  Eighty evaluable patients were randomized, 39 to BMT-VR and 41 to usual care. Completion rates for the BMT-VR modules were high [at] around 70-75%.  Patients who received the BMT-VR intervention experienced significantly improved anxiety, quality of life, and coping at 4 weeks post-BMT. In the longer term, sustained benefits were seen at 24 weeks for some endpoints including quality of life, with some benefits, including for depression and PTSD symptoms, improving longitudinally over the study period. These data are preliminary and will need to be confirmed in larger multicenter studies, but this trial demonstrates the feasibility of using virtual interventions in our patients and also provides intriguing preliminary data that they may be effective. Thanks for listening to today's report and I hope you will join me again tomorrow to hear more top takeaways from the final day of ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.   Disclaimer:   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     Find out more about today's speaker:     Dr. John Sweetenham       Follow ASCO on social media:      @ASCO on Twitter     @ASCO on Bluesky     ASCO on Facebook     ASCO on LinkedIn       Disclosures:    Dr. John Sweetenham:     No relationships to disclose 

En este episodio, Figo comparte su experiencia personal sobre el aprendizaje de idiomas, centrándose en la importancia de un libro específico que le ayudó a acelerar su proceso de aprendizaje del noruego y el inglés. Destaca la relevancia de enfocarse en las primeras mil palabras y las reglas gramaticales fundamentales para facilitar la comunicación básica. Además, enfatiza la posibilidad de aprender de manera autodidacta y la eficiencia en el uso del tiempo y recursos.Capítulos:00:00 Introducción al Aprendizaje de Idiomas02:28 La Importancia de las Primeras Mil Palabras04:50 Metodología de Aprendizaje Eficiente07:33 Aplicación de la Metodología en Noruego09:56 Reflexiones Finales sobre el Aprendizaje de Idiomas

En este episodio, Marcela Nurnberg y Figo discuten la importancia del coraje en el proceso de migración, explorando cómo enfrentar el desafío de empezar de cero en un nuevo país y cultura. Hablan sobre la necesidad de reconstruir el amor propio y superar la arrogancia, así como la importancia de aprender un nuevo idioma y cómo esto requiere valentía y perseverancia. El coraje es un valor fundamental que permite a los migrantes superar obstáculos y adaptarse a su nueva realidad. iradoras de coraje y superación de otros migrantes.Más información sobre nuestro taller Capital MAAS:www.somosMAAS.noCapítulos:00:00 Introducción al Coraje en la Migración05:40 El Coraje de Empezar de Cero10:01 El Amor Propio y la Arrogancia15:44 El Desafío del Aprendizaje de Idiomas20:48 La Realidad del Idioma y la Adaptación23:05 Aprendiendo de los Errores25:30 El Coraje de Emprender29:32 La Identidad Multicultural33:03 El Mensaje a Nuestros Hijos37:05 Cultivando el Coraje40:59 Historias de Coraje y Superación

En este episodio del podcast de Noruega, Marcela y Figo anuncian su primer taller dirigido a migrantes de alta ambición de superación. A lo largo de la conversación, discuten la importancia de la capitalización de habilidades y experiencias, así como los desafíos que enfrentan los migrantes en su adaptación a la sociedad noruega. Enfatizan la necesidad de construir una comunidad y establecer conexiones significativas para facilitar el proceso de integración.Más info del taller:www.somosmaas.noTemas del episodio:00:00 Bienvenida y Anuncio del Taller01:48 Concepto de Migrante Más03:45 El Test de Autodiagnóstico: www.somosmaas.no05:39 La Teoría del Capital y su Importancia09:13 Descapitalización y Adaptación Cultural11:12 Códigos Sociales y Primeras Impresiones12:41 Estructura del Taller15:16 Construyendo Vínculos y Comunidad

En este episodio, Figo y Marcela exploran la ambición como un valor fundamental para los migrantes en Noruega. Discuten cómo la ambición puede ser vista de manera positiva y cómo es esencial para el crecimiento personal y profesional. A través de reflexiones sobre sus propias experiencias, abordan los estigmas que enfrentan los migrantes y la importancia de creerse capaces de alcanzar sus sueños. Además, comparten ejemplos inspiradores de miembros de la comunidad que han logrado el éxito a pesar de los desafíos.Capítulos00:00 La Ambición como Valor Fundamental02:51 Desmitificando la Alta Ambición05:57 Reflexiones sobre el Rol del Migrante08:57 Creer en Nuestras Capacidades12:02 Empoderamiento y Ambición14:57 Recomendaciones y Redes de Apoyo16:48 Descubrimiento de Oportunidades Laborales17:58 Percepción del Inmigrante en Noruega19:48 Rebelión y Empoderamiento del Inmigrante23:54 Ambición y Proceso de Crecimiento27:12 Historias Inspiradoras de la Comunidad31:44 Cierre y Reflexiones Finales✅ Si la información de este episodio te ayudó, nos encantaría que nos califiques positivamente en Spotify.

Support #Millennial! Pledge on Patreon and receive lots of perks: https://patreon.com/millennial Visit our merch store: https://shop.millennialshow.com Watch episodes on YouTube: https://www.youtube.com/@millennialpodcast Please don't panic buy: we're tracking the incoming economic storm sparked by the latest tariffs on Chinese goods. When EXACTLY will prices increase and availability drop? We have new reporting that reveals the timeline. If store shelves still look full for now, that's because products are still making their slow journey across the Pacific—but the ripple effects are just beginning. We also feature a ton of great listener feedback this week, from a slew of Confessionals (#tellusyoursecrets), to follow ups on our recent fitness and "mini retirement" conversations on the show. And you know we'd never leave you without recommendations: Figo pet insurance (Andrew) and the latest season of 'Black Mirror' on Netflix (Laura). And in this week's installment of After Dark, we opened up the floor to Patrons to ask us their most burning questions about MuggleSuck, being child-free by choice, as well as some personal anecdotes that we can only share behind the paywall... Want to tune in? Support us over at Patreon! Learn more about your ad choices. Visit megaphone.fm/adchoices

En episodio especial, Figo reflexiona sobre tres cosas que habría hecho diferente si tuviera que volver a empezar en Noruega. Un episodio ideal para quienes están empezando la aventura de migrar, o bien la tienen en mente.✅ Si la información de este episodio te ayudó, nos encantaría que nos califiques positivamente en Spotify.

Tal día como hoy,  el 16 abril de 1969, Germán Adrián Ramón Mono Burgos Maestromey nace en la ciudad del Mar del Plata (Argentina), portero que vistió la rojiblanca durante 3 temporadas (desde la 2001/02 hasta la2003/04) y, posteriormente, mano derecha de Diego Pablo Simeone en el banquillo en el Atlético de Madrid durante 9 temporadas, en una de las mejores etapas de la historia del club. De entre todos los recuerdos que nos han quedado de él, destaca aquel penalti que paró con la cara a Figo en el derbi en la cuadra que supuso un empate a 2 en nuestro retorno a 1ª, pudiéndose decir que sangró por el Atleti. Tampoco podemos dejar de mencionar su icónica imagen saliendo de una alcantarilla en la campaña publicitaria del retorno del infierno. En el campeonato nacional de Liga, el lunes en partido disputado a las 21:00 en el Metropolitano, el Atleti  ganó por 4-2 al colista de la clasificación, el R. Valladolid. Un partido sin historia en que pareció que la lluvia que caía sobre el estadio contagió a los nuestros, pero que en cuanto pisaron un poco el acelerador lograron los 3 puntos para seguir creyendo en que matemáticamente no hay nada decidido. El siguiente partido será el próximo Sábado Santo, a las 21:00 horario peninsular, en el Estadio de Gran Canaria, frente a la U.D.  Las Palmas. Disfruten del programa.  SUMARIO:1.- Presentación 2.- Las batallas del abuelo  3.- El cuadernillo de Óscar con @elabuchus4.-Jesús en un bar con @Doniphon62 “I wouldn't change a thing” de Ray LaMontagnel5.- Tertulia Atlética con @martamredondo7 @PineroGomez1 @chaminorte y @MiguelNicolasOS  6.- “Atípico” escrito por  @MiguelNicolasOS Todo ello presentado y dirigido por Eduardo de Atleti (@EduardoDeAtleti) Podéis dejar vuestras opiniones sobre este programa, tanto en los comentarios de esta entrada, como en Spreaker.com, iVoox.com, Twitter y Facebook Tienen todas las melodías y músicas del programa en esta lista de SpotifyConviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/aplasta-arteche-podcast--4791815/support.

Tal día como hoy,  el 16 abril de 1969, Germán Adrián Ramón Mono Burgos Maestromey nace en la ciudad del Mar del Plata (Argentina), portero que vistió la rojiblanca durante 3 temporadas (desde la 2001/02 hasta la2003/04) y, posteriormente, mano derecha de Diego Pablo Simeone en el banquillo en el Atlético de Madrid durante 9 temporadas, en una de las mejores etapas de la historia del club. De entre todos los recuerdos que nos han quedado de él, destaca aquel penalti que paró con la cara a Figo en el derbi en la cuadra que supuso un empate a 2 en nuestro retorno a 1ª, pudiéndose decir que sangró por el Atleti. Tampoco podemos dejar de mencionar su icónica imagen saliendo de una alcantarilla en la campaña publicitaria del retorno del infierno. En el campeonato nacional de Liga, el lunes en partido disputado a las 21:00 en el Metropolitano, el Atleti  ganó por 4-2 al colista de la clasificación, el R. Valladolid. Un partido sin historia en que pareció que la lluvia que caía sobre el estadio contagió a los nuestros, pero que en cuanto pisaron un poco el acelerador lograron los 3 puntos para seguir creyendo en que matemáticamente no hay nada decidido. El siguiente partido será el próximo Sábado Santo, a las 21:00 horario peninsular, en el Estadio de Gran Canaria, frente a la U.D.  Las Palmas. Disfruten del programa.  SUMARIO:1.- Presentación 2.- Las batallas del abuelo  con Eduardo Fernández de @UnionATM3.- El cuadernillo de Óscar con @elabuchus4.-Jesús en un bar con @Doniphon62 “I Love this bar” de Toby Keith5.- Tertulia Atlética con @jorgelerabox  @Lera_atm94 @chaminorte y @martamredondo7 como @MiguelNicolasOS 6.- “Barrios” escrito por  @MiguelNicolasOS Todo ello presentado y dirigido por Eduardo de Atleti (@EduardoDeAtleti) Podéis dejar vuestras opiniones sobre este programa, tanto en los comentarios de esta entrada, como en Spreaker.com, iVoox.com, Twitter y Facebook Tienen todas las melodías y músicas del programa en esta lista de SpotifyConviértete en un seguidor de este podcast: https://www.spreaker.com/podcast/aplasta-arteche-podcast--4791815/support.

Gil Vicente e Benfica disputam o jogo em atraso, Jesus apontado ao Brasil e Figo indignado

Il nostro podcast è sostenuto da NordVPN ➤➤➤ https://nordvpn.com/dufer Con il codice DAILYCOGITO7 puoi iniziare un percorso su Serenis per prenderti cura del tuo benessere mentale a un prezzo convenzionato. Scopri di più su https://www.serenis.it/influencer/daily-cogito?utm_source=influencer&utm_medium=affiliate&utm_campaign=DAILYCOGITO7&utm_content=podcast&utm_term=host+read ⬇⬇⬇SOTTO TROVI INFORMAZIONI IMPORTANTI⬇⬇⬇ Abbonati per live e contenuti esclusivi ➤➤➤ https://bit.ly/memberdufer I prossimi eventi dal vivo ➤➤➤ https://www.dailycogito.com/eventi Scopri la nostra scuola di filosofia ➤➤➤ https://www.cogitoacademy.it/ Racconta storie di successo con RISPIRA ➤➤➤ https://cogitoacademy.it/rispira/ Impara ad argomentare bene ➤➤➤ https://bit.ly/3Pgepqz Prendi in mano la tua vita grazie a PsicoStoici ➤➤➤ https://bit.ly/45JbmxX Il mio ultimo libro per Feltrinelli ➤➤➤ https://amzn.to/3OY4Xca La newsletter gratuita ➤➤➤ http://eepurl.com/c-LKfz Tutti i miei libri ➤➤➤ https://www.dailycogito.com/libri/ Il nostro podcast è sostenuto da NordVPN ➤➤➤ https://nordvpn.com/dufer ù #sanremo #sanremo2025 #autotune INSTAGRAM: https://instagram.com/rickdufer INSTAGRAM di Daily Cogito: https://instagram.com/dailycogito TELEGRAM: http://bit.ly/DuFerTelegram FACEBOOK: http://bit.ly/duferfb LINKEDIN: https://www.linkedin.com/pub/riccardo-dal-ferro/31/845/b14 -------------------------------------------------------------------------------------------- Chi sono io: https://www.dailycogito.com/rick-dufer/ -------------------------------------------------------------------------------------------- La musica della sigla è tratta da Epidemic Sound (author: Jules Gaia): https://epidemicsound.com/ - la voce della sigla è di CAROL MAG (https://www.instagram.com/carolmagmusic/) Learn more about your ad choices. Visit megaphone.fm/adchoices

Ce matin, Bruno reçoit le talentueux DJ El Figo, un jeune garçon de 13 ans qui mixe à la perfection.

O Doutor dá as boas vindas à direita a várias personalidades que estavam no armário: Dr. Gustavo Santos, Dr. Rui Sinel de Cordes, Dr. Carlos Figo e Dr. Mark Zuckerberg. Bilhetes para "Um Salazar Em Cada Esquina": https://linktr.ee/odoutorjcd Com o apoio da cockburn's: https://www.instagram.com/cockburns_port/ Segmento extra em: https://www.patreon.com/jcdireita Instagram: https://www.instagram.com/jovemconservadordedireita Anda tudo a mamar: https://youtu.be/igrGXcPBTrI?si=Qrj22zQqzN-B-vBI

Bruno Lage, Tozé Marreco, Rui Silva no Spoting, Rui Costa nas compras, Vítor Bruno, Union Berlin, Luís Figo e muito mais...

In this week's Reminding You Why You Love Football, Owen Blackhurst is back in the big chair, and is babysitting Asad Raza and Matt O'Connor-Simpson to talk about dark times, audience retention, 5 stars, the joy of Discord, the skip incident, James in Milano, three pints and 18 fags, Asad Bird-White, The Legion of Gloom of Longform, two internationals in 48 hours, an audience with Tommy Gravesen, hats off to Hummel, having no skin in the game, coaching mode, Marc Cucurella, quiz-meister Seb on the ale, Matt on the Spot, Colin Wanker, Asad's peak, The Naked Gun, PlayStation memories, FIFA fallouts and sulky losers, throwing down the gauntlet, bumbling around Germany, Baller League, KSI, a wooden Figo and Ronaldinho in a kimono, dodgy promos, a Trump trivela, Salah's torso, Owen on the Jack Kerouac in size 14s, the Bukowski of badge kissing, the Hemingway of hat-tricks—Van Hooijdonk, knowing your value, telling it straight, banging in goals and banging kits, Turkish fans on social, Chris Wood, build your own St Pierre, outing Matt, Claude Puel, Arda in the limelight, Hooijdonk at Fenerbahçe, right place: right time, Peep Show, warm-ups, photo evidence, hard balls, football lingo, Dobby Club, Matt on the Spot again!, Arne Slott penitentiary candidates, Ancelotti at Everton, power cuts, “air quotes”, Craig Bellamy in his element, characters, nice cults, Keane at Ipswich, being rude, Owen giving the eye, phoning it in, falling off your bike, a cupping session, wellness, listening to your elders, looking up a setlist, Seb on the line from his sick bed, shit on the pillow, and somehow so much more.Get the latest issue of MUNDIAL Mag hereFollow MUNDIAL on X - @mundialmagFollow MUNDIAL on Instagram - @mundialmag Hosted on Acast. See acast.com/privacy for more information.

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Domenica Lorusso to discuss  KEYNOTE-A18 Overall Survival Results: Pembrolizumab and Chemoradiotherapy. Dr. Domenica Lorusso, MD, PhD, directs the Gynaecological Oncology Unit at Humanitas Hospital, Milan, and holds a Full Professorship in Obstetrics and Gynaecology at Humanitas University, Rozzano, Milan. She has led/participated in approximately 250 phase I-IV clinical trials. Currently overseeing more than 60 studies as Principal Investigator, Dr. Lorusso also chairs the Clinical Trials Committee of the MITO Group. She serves on the Board of Directors of the GCIG and is an active member of ENGOT, where she chairs the Gynecological Cancer Academy. Additionally, she sits on the Board of Directors of the ESGO. With around 300 international oncology publications and contributions to national and international treatment guidelines, her primary objectives are to ensure optimal patient care, foster clinical research, and advance international collaborations and education in the field. Highlights:  In a phase 3 trial (ENGOT-cx11/GOG-3047/KEYNOTE-A18), pembrolizumab added to chemoradiotherapy significantly improved progression-free survival and overall survival for patients with locally advanced, high-risk cervical cancer. Patient Group: 1060 patients with FIGO 2014 stage IB2–IVA cervical cancer from 30 countries were randomized to receive pembrolizumab with chemoradiotherapy or placebo with chemoradiotherapy. Overall Survival: At a median follow-up of 29.9 months, the 36-month overall survival rate was 82.6% in the pembrolizumab group versus 74.8% in the placebo group, with a hazard ratio for death of 0.67 (95% CI 0.50–0.90; p=0.0040). Safety Profile: Grade 3 or higher adverse events were reported in 78% of pembrolizumab-treated patients versus 70% in the placebo group, with higher rates of potentially immune-mediated adverse events in the pembrolizumab group (39% vs. 17%). Conclusion: These findings confirm pembrolizumab plus chemoradiotherapy as an effective and potentially new standard of care for locally advanced cervical cancer.

It's Halloween 2024 and I could not think of anything more fitting than to bring back that quarky little character called Mr Bones. I have featured this tiny TikTok Sensation a few times now on the podcast and it's always super fun to chat with Kimberlee about Mr. Bones with fun Halloween tidbits sprinkled in. Today, I'll welcome to the podcast – Kimberlee Peers Moore Find the Mr. Bones Sews on Instagram at https://www.instagram.com/mr.bones_sewsWant to travel with Brandy?2025 FESTIVAL OF QUILTS Birmingham!!! This 14-day tour of Wales and England takes in the rich textile history and breathtaking cultural landmarks. Tour England & Wales ending at the Festival of Quilts. Call Judy at 1-877-235-3767 or go to  https://opulentquiltjourneys.com/destinations/britain/item/birmingham-festival-of-quilts-tour-with-brandy2026 JAPAN CRUISE!!! Watergirl Quilt Co and the Quilter on Fire have teamed up to sail the seas on the Celebrity Millennium. Sail with us on a JAPAN CRUISE in 2026! Registration is OPEN and this cruise is already 50% sold! SIGN UP TODAY!https://gravitate.travel/stitch-sail-japan-with-quilter-on-fire-and-watergirl-quilt-co/Quilter on Fire Website - https://quilteronfire.com/OLISO IRONS - Host of the Quilter on Fire Podcast Lounge each year at QuiltCon!BUY YOUR OWN OLISO MINI PROJECT IRON RIGHT HERESquare One Textile Art WorkshopLink to Brandy's email listKristy's Quilt Picture BookQuilter on Fire PatternsFree Quilter on Fire Holiday Table Runner VIDEO Moving Train Car by Anavrin.KIMBERLEE60599 for 10% offRolife Super Creator DIY rooms ( Bubble tea shop, Tea Room)Mr.Bones15 for 15% offReal World Mini ( Mini Blender)MRBONES for 10% offOrmkraft Rotary cutters and matsBONES10 for 10% off Fifi Joy The Dutchesses Closet, so many tiny pieces were still working on itMRBONES for 20% off!Some notions we talked about:https://ormkraft.com/https://feralnotions.com/en-cahttps://www.stitchsupplyco.com/products/quilt-binding-spool?srsltid=AfmBOooVdZj9V5_-VIh21SP362ovFLsEpfCa_DIJUvDAZV9sj48xQyINHere's a link to FIGO fabrics if you are a store and you want to bring in some new stock! https://www.figofabrics.com/contact-us.aspxSupport the showThank you for listening to the Quilter on Fire Podcast.

Nadeem Abu-Rustum bio: Dr. Abu-Rustum is a board-certified gynecologic oncologist who specializes in the surgical treatment of gynecologic cancers at Memorial Sloan Kettering Cancer Center. He is also a professor of obstetrics and gynecology at Weill Cornell Medical College. Dr. Abu-Rustum has a special interest in minimally invasive surgery (laparoscopy) for the treatment of cancerous and noncancerous diseases of the female reproductive system, and his clinical research focuses on surgical therapy for gynecologic cancers and innovative surgical approaches to treating gynecologic disorders. Christian Dagher bio: Christian Dagher is a former research fellow at Memorial Sloan Kettering, and current OBGYN resident at the University of Pennsylvania. He holds a master's degree in clinical epidemiology and health-services research from Weill-Cornel. Before moving to the US, he completed an OBGYN residency at the American University of Beirut and is interested in studying survival biomarkers in endometrial cancer.  Highlights: The 2023 FIGO staging system for endometrioid endometrial carcinomas included the extent of lymphovascular invasion as a determinant of stage. The new staging system, groups tumors with no lymphovascular space invasion and those with focal invasion (

The ACOG defines Fetal Growth Restriction (FGR) as fetuses with an estimated fetal weight or abdominal circumference that is less than the 10th percentile for gestational age. Currently, the ACOG, SMFM, FIGO, and the ISUOG do not recommend maternal bed rest for this condition. However, a recent publication from the AJOG (May 2024) concluded that strict maternal bed rest could in fact reverse FGR in a short two-week interval! Is this possible? In this episode, we will dissect this controversial, retrospective study and give it proper perspective with real world clinical implications.